Is APVO or ARQT more undervalued in 2026?

CirclFi compares Aptevo Therapeutics Inc. (APVO) and Arcutis Biotherapeutics, Inc. (ARQT) using 13 institutional-grade valuation models. APVO has a Quality of Company score of 4.2/10 while ARQT scores 6.2/10.

Which is a better buy — APVO or ARQT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APVO and ARQT valuations compare?

APVO at $5.00 and ARQT at $21.44 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APVO vs ARQT Valuation Comparison 2026 — Intrinsic Value Analysis

APVO

Biotechnology

Aptevo Therapeutics Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$5.00

Last close

Models

6/13

Active

ARQT

Biotechnology

Arcutis Biotherapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$21.44

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	APVO Fair Value	APVO Upside	ARQT Fair Value	ARQT Upside
Bayesian DCF	Intrinsic	$6.12	+22.5%	$6.25	-70.9%
Earnings Power Value	Intrinsic	—	—	$3.91	-83.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.36	-92.6%	$0.55	-97.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APVO vs ARQT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APVO vs ARQT — Which Stock Is More Undervalued?

ARQT scores higher with a 6.2/10 quality rating vs APVO's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aptevo Therapeutics Inc. (APVO) and Arcutis Biotherapeutics, Inc. (ARQT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APVO currently trades at $5.00 with a QOC of 4.2/10, while ARQT trades at $21.44 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).